Analysis of the Efficacy of Cardiac Ischemic Postconditioning With New Clinical End-points Using Novel Biomarkers
Primary Purpose
Acute Myocardial Infarction With ST Elevation
Status
Completed
Phase
Not Applicable
Locations
Hungary
Study Type
Interventional
Intervention
Postconditioning
Percutaneous coronary intervention
Sponsored by
About this trial
This is an interventional basic science trial for Acute Myocardial Infarction With ST Elevation focused on measuring ischemic postconditioning, acute myocardial infarction, Investigator Initiated Trial, biomarker, coronary artery disease, ischemic, postconditioning, infarction, infarct size, area at risk, coronary occlusion, balloon catheter, percutaneous coronary intervention, PCI, MRI
Eligibility Criteria
Inclusion Criteria:
- Subject must be >18 years of age
- Myocardial infarction with elevated ST
- Chest pain onset less than 12 hours before PCI
- concordant ST elevation (>0,1 mV) in at least 2 ECG leads
- Occluded main proximal or middle main coronary ('Thrombolysis In Myocardial Infarction' flow grade: 0) diagnosed with coronarography
- Coronary opened by PCI (TIMI 2 flow grade)
- Awake, conscious, co-operating patient, who is able to retain his breath for 10 sec
- Signed Patient Information Leaflet and Patient Informed Consent Form
Exclusion Criteria:
- Cardiogenic shock
- Previous myocardial infarction in the area of the occluded coronary artery
- Occluded coronary with visible collateral branches
- Lack of co-operation
- Current left or right bundle branch block (LBBB)
- Malignant ventricle arrhythmia or atrial fibrillation
- Killip class > 2
- Known renal failure
Sites / Locations
- Heart and Vascular Center, Semmelweis University
- Pharmahungary Group
- Department of Invasive Cardiology of Cardiology Center, Faculty of Medicine, University of Szeged
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
postconditioning
control
Arm Description
Patients that underwent postconditioning after primary percutaneous coronary intervention.
Patients that underwent primary percutaneous coronary intervention.
Outcomes
Primary Outcome Measures
Cardiac magnetic resonance imaging
Left and right ventricular function, myocardial scar, transmurality, diffusion spectrum imaging (DSI) measurement and evaluation
Secondary Outcome Measures
Echocardiography measurement of Cardiac Ejection Fraction
Measurement of Cardiac Ejection Fraction using Teicholz and Simpson methods on both study arms.
Echocardiography measurement of cardiac left ventricular segments for wall motion abnormalities
Calculation of cardiac wall motion score index on both study arms.
Laboratory measurement of blood Nitrotyrosine levels.
Laboratory measurement of Nitrotyrosine levels in blood samples with ELISA on both study arms.
Laboratory measurement of blood MMP activity.
Laboratory measurement of MMP activity in blood samples with zymography on both study arms.
Laboratory characterization of microRNA patterns with microRNA array
Laboratory characterization of microRNA expression pattern in blood samples with with microRNA array on both study arms.
Validation of selected microRNA with quantitative real-time PCR
Out of the differentially expressed microRNAs identified in Outcome 6, up to 10 different miRNAs will be selected for further validation of their specific expression change (expressed by fold-change) by quantitative real-time PCR in up to 10 randomly selected patients on both study arms, respectively.
Electrocardiography ST segment post-procedure evaluation
Distortion in ST segment amplitude in millivolt (mV) and duration measured in milliseconds (ms) after procedure measured by 12-lead Electrocardiography (ECG) will be evaluated on both study arms.
Electrocardiography T wave post-procedure evaluation
Distortion in T wave amplitude in millivolt (mV) and duration measured in milliseconds (ms) after procedure measured by 12-lead Electrocardiography (ECG) will be evaluated on both study arms.
Full Information
NCT ID
NCT04824716
First Posted
March 8, 2021
Last Updated
April 19, 2021
Sponsor
Peter Ferdinandy
Collaborators
Semmelweis University Heart and Vascular Center, Szeged University
1. Study Identification
Unique Protocol Identification Number
NCT04824716
Brief Title
Analysis of the Efficacy of Cardiac Ischemic Postconditioning With New Clinical End-points Using Novel Biomarkers
Official Title
Evaluation of the Efficacy and Biochemical Characteristics of Ischemic Postconditioning in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
January 14, 2013 (Actual)
Primary Completion Date
October 15, 2018 (Actual)
Study Completion Date
October 15, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Peter Ferdinandy
Collaborators
Semmelweis University Heart and Vascular Center, Szeged University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the present study was to investigate the efficacy of ischemic postconditioning in acute myocardial infarction patients. The safety of patients enrolled in the study was ensured during the entire study. Over 18 years old men and women were enrolled in the study who arrived to 2 of the most acknowledged Hungarian cardiac centres due to acute myocardial infarction and fulfilled all inclusion and exclusion criteria as per protocol. Patients in the order of their arrival were assigned either to control or post conditioned groups by turns. Medical treatment of the control group was done according to standard Percutaneous Coronary Intervention (PCI) guidelines, i.e. there was no further intervention after artery opening for 8 minutes, then stenting was performed. In the post conditioned group, after reperfusion has been confirmed, the coronary artery was occluded by inflation of the stent balloon 4 times (for 1-1 minute) followed by 1-1-minute reperfusion repeatedly to induce ischemic postconditioning. Postconditioning procedure was followed by stenting as in the control group. All other interventions and treatments in both patient groups were identical according to guidelines.
Detailed Description
Over 18 years old men and women were enrolled in the study who arrived to 2 of the most acknowledged Hungarian cardiac centres due to acute myocardial infarction and fulfilled all inclusion and exclusion criteria as per protocol. Patients in the order of their arrival were assigned either to control or post conditioned groups by turns. After closing patient enrolment, further subgrouping will be performed in case sufficient group size has been achieved as follows: (1) normal, control, (2) normal, post conditioned, (3) hypercholesterolemic, not treated with statins, control, (4) hypercholesterolemic, not treated with statins, post conditioned, (5) statin treated, control, (6) statin treated, post conditioned.
Characterisation of postconditioning is performed by the following parameters:
Blood tests 5 minutes before as well as 8, 60 minutes, 24 hours, and 3 months after PCI to measure nitrotyrosine, a biomarker of peroxynitrite formation (nitrosative stress) by ELISA; B-type natriuretic peptide, a biomarker of heart failure by ELISA; matrix metalloproteinase activities (MMP-2 and MMP-9) putative biomarkers of cardiac remodelling by zymography; microRNA expression pattern by sequencing and its validation by quantitative real-time polymerase chain reaction (PCR).
Routine laboratory tests 6, 12 and 48 hours after PCI including creatine kinase (CKMB) and cardiac troponin T (cTnT).
ECG immediately after recanalization and intervention after 60 and 90 minutes, then 12, 24, 36 and 48 hours later 12-lead ECG is registered.
Echocardiography: 48 hours after intervention, standard view to judge left ventricle segments movement disorders
Angiography: Blush, Syntax score, and ischemic risk zone (area at risk, AAR) are determined
cardiac late enhancement magnetic resonance (MR) imaging to determine infarct size
At 3-month follow-up visit the following parameters were measured: echocardiography for restitution assessment, cardiac late enhancement MR imaging to determine infarct size and cardiac function, blood sampling for above mentioned biochemical laboratory tests
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Myocardial Infarction With ST Elevation
Keywords
ischemic postconditioning, acute myocardial infarction, Investigator Initiated Trial, biomarker, coronary artery disease, ischemic, postconditioning, infarction, infarct size, area at risk, coronary occlusion, balloon catheter, percutaneous coronary intervention, PCI, MRI
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
postconditioning
Arm Type
Experimental
Arm Description
Patients that underwent postconditioning after primary percutaneous coronary intervention.
Arm Title
control
Arm Type
Other
Arm Description
Patients that underwent primary percutaneous coronary intervention.
Intervention Type
Procedure
Intervention Name(s)
Postconditioning
Intervention Description
The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
Intervention Type
Device
Intervention Name(s)
Percutaneous coronary intervention
Intervention Description
Percutaneous coronary intervention as per European Society of Cardiology guidelines.
Primary Outcome Measure Information:
Title
Cardiac magnetic resonance imaging
Description
Left and right ventricular function, myocardial scar, transmurality, diffusion spectrum imaging (DSI) measurement and evaluation
Time Frame
3 months after acute myocardial infarction
Secondary Outcome Measure Information:
Title
Echocardiography measurement of Cardiac Ejection Fraction
Description
Measurement of Cardiac Ejection Fraction using Teicholz and Simpson methods on both study arms.
Time Frame
48 hours and 3 months after acute myocardial infarction
Title
Echocardiography measurement of cardiac left ventricular segments for wall motion abnormalities
Description
Calculation of cardiac wall motion score index on both study arms.
Time Frame
48 hours and 3 months after acute myocardial infarction
Title
Laboratory measurement of blood Nitrotyrosine levels.
Description
Laboratory measurement of Nitrotyrosine levels in blood samples with ELISA on both study arms.
Time Frame
5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Title
Laboratory measurement of blood MMP activity.
Description
Laboratory measurement of MMP activity in blood samples with zymography on both study arms.
Time Frame
5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Title
Laboratory characterization of microRNA patterns with microRNA array
Description
Laboratory characterization of microRNA expression pattern in blood samples with with microRNA array on both study arms.
Time Frame
5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Title
Validation of selected microRNA with quantitative real-time PCR
Description
Out of the differentially expressed microRNAs identified in Outcome 6, up to 10 different miRNAs will be selected for further validation of their specific expression change (expressed by fold-change) by quantitative real-time PCR in up to 10 randomly selected patients on both study arms, respectively.
Time Frame
5 minutes before PCI as well as 8 minutes after, 60 minutes, 6, 12, 24, 48 hours, and 3 months after acute myocardial infarction
Title
Electrocardiography ST segment post-procedure evaluation
Description
Distortion in ST segment amplitude in millivolt (mV) and duration measured in milliseconds (ms) after procedure measured by 12-lead Electrocardiography (ECG) will be evaluated on both study arms.
Time Frame
Post-procedure 60, 90 minutes, and 12, 24, 48 hours.
Title
Electrocardiography T wave post-procedure evaluation
Description
Distortion in T wave amplitude in millivolt (mV) and duration measured in milliseconds (ms) after procedure measured by 12-lead Electrocardiography (ECG) will be evaluated on both study arms.
Time Frame
Post-procedure 60, 90 minutes, and 12, 24, 48 hours.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject must be >18 years of age
Myocardial infarction with elevated ST
Chest pain onset less than 12 hours before PCI
concordant ST elevation (>0,1 mV) in at least 2 ECG leads
Occluded main proximal or middle main coronary ('Thrombolysis In Myocardial Infarction' flow grade: 0) diagnosed with coronarography
Coronary opened by PCI (TIMI 2 flow grade)
Awake, conscious, co-operating patient, who is able to retain his breath for 10 sec
Signed Patient Information Leaflet and Patient Informed Consent Form
Exclusion Criteria:
Cardiogenic shock
Previous myocardial infarction in the area of the occluded coronary artery
Occluded coronary with visible collateral branches
Lack of co-operation
Current left or right bundle branch block (LBBB)
Malignant ventricle arrhythmia or atrial fibrillation
Killip class > 2
Known renal failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Béla Merkely, MD, PhD
Organizational Affiliation
Heart and Vascular Center, Semmelweis University, Budapest
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Peter Ferdinandy, MD, PhD, MBA
Organizational Affiliation
Pharmahungary Group
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Imre Ungi, MD, PhD
Organizational Affiliation
University of Szeged, Faculty of Medicine, Cardiology Center, Department of Invasive Cardiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Heart and Vascular Center, Semmelweis University
City
Budapest
ZIP/Postal Code
H-1122
Country
Hungary
Facility Name
Pharmahungary Group
City
Szeged
ZIP/Postal Code
6722
Country
Hungary
Facility Name
Department of Invasive Cardiology of Cardiology Center, Faculty of Medicine, University of Szeged
City
Szeged
ZIP/Postal Code
H-6720
Country
Hungary
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
http://www.pharmahungary.com
Description
Website of Pharmahungary Group.
URL
http://vszek.semmelweis.hu/homepage
Description
Website of Semmelweis University Heart and Vascular Center.
URL
http://www.med.u-szeged.hu/english
Description
Website of Department of Invasive Cardiology of Cardiology Center, Faculty of Medicine, University of Szeged.
Learn more about this trial
Analysis of the Efficacy of Cardiac Ischemic Postconditioning With New Clinical End-points Using Novel Biomarkers
We'll reach out to this number within 24 hrs